BWAY - BrainsWay: Cash Flows Are Underappreciated
2024-05-09 09:00:33 ET
Summary
- BrainsWay reported strong Q1 results with profitability, positive cash flow, and strong growth.
- Market conditions have supposedly affected Neuronetics, but BrainsWay has not experienced similar problems.
- BrainsWay continues to expand its installed base and is exploring new indications for TMS treatment.
- Even ignoring upside from new indications, BrainsWay stock is deeply undervalued based on its cash balance and current cash flows.
BrainsWay ( BWAY ) reported strong results again in the first quarter, with continued profitability, positive free cash flow and strong growth. This strength is particularly notable in light of Neuronetics' ( STIM ) relatively soft quarter, which the company attributed to the macro environment....
BrainsWay: Cash Flows Are Underappreciated